Literature DB >> 20440502

Central nervous system manifestations of marginal zone B-cell lymphoma.

Soley Bayraktar1, Alexandra Stefanovic, Naomi Montague, Janet Davis, Timothy Murray, Izidore S Lossos.   

Abstract

Primary or secondary central nervous system (CNS) involvement by marginal zone B-cell lymphoma (MZBCL) is rare. A retrospective analysis of patients was done with MZBCL involving the CNS, diagnosed and treated at our institution between 2004 and 2010. We identified 10 MZBCL patients with primary (six) or secondary (four) CNS involvement. Five patients presented with primary dural lymphoma and were treated with surgical resection, whole-brain radiation, or systemic chemotherapy. Only one patient had CNS relapse 5 years later. A single patient with primary intraocular lymphoma achieved clinical remission with ocular radiotherapy and systemic chemotherapy. Four patients had ocular MZBCL within 5 years of the initial diagnosis of primary ocular adnexal MZBCL and primary splenic MZBCL. There was no evidence of local recurrence in all but one who developed systemic relapse after 3 years of follow-up. Primary or secondary CNS involvement by MZBCL display indolent clinical behavior and have a generally favorable prognosis, underlining the importance of their differentiation from aggressive lymphomas that more commonly involve the CNS.

Entities:  

Mesh:

Year:  2010        PMID: 20440502     DOI: 10.1007/s00277-010-0976-3

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  17 in total

1.  Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement.

Authors:  Fateeha Furqan; Grace Watson; Felipe Samaniego; Luis E Fayad; Michael W Morrison; Philip A Thompson; Raphael E Steiner; Linda Chi; Bouthaina Dabaja; Chelsea C Pinnix; Sattva S Neelapu; Loretta J Nastoupil; Paolo Strati
Journal:  Leuk Lymphoma       Date:  2020-07-10

2.  77-year-old woman with a dural-based mass. Marginal zone B-cell lymphoma (MZBCL).

Authors:  Ross A Okimoto; Arie Perry; James L Rubenstein
Journal:  Brain Pathol       Date:  2015-01       Impact factor: 6.508

3.  Marginal zone lymphomas involving meningeal dura: possible link to IgG4-related diseases.

Authors:  Girish Venkataraman; Kathryn A Rizzo; Jessica J Chavez; Berthold Streubel; Mark Raffeld; Elaine S Jaffe; Stefania Pittaluga
Journal:  Mod Pathol       Date:  2010-11-19       Impact factor: 7.842

Review 4.  SOHO State of the Art Updates and Next Questions: Prophylaxis and Management of Secondary CNS Lymphoma.

Authors:  Jillian Simard; Mark Roschewski
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2022-06-06

5.  Chemotherapy is an efficient treatment in primary CNS MALT lymphoma.

Authors:  Clément Desjardins; Delphine Larrieu-Ciron; Sylvain Choquet; Karima Mokhtari; Frédéric Charlotte; Lucia Nichelli; Bertrand Mathon; Guido Ahle; Magali Le Garff-Tavernier; Andrea Morales-Martinez; Caroline Dehais; Khê Hoang-Xuan; Caroline Houillier
Journal:  J Neurooncol       Date:  2022-06-20       Impact factor: 4.506

6.  Primary Dural Mucosa-associated Lymphoid Tissue Lymphoma Mimicking Falx Meningioma: A Case Report.

Authors:  Issei Takeuchi; Takafumi Tanei; Kyoko Kuwabara; Takenori Kato; Takehiro Naito; Yuta Koketsu; Kento Hirayama; Toshinori Hasegawa
Journal:  NMC Case Rep J       Date:  2022-05-31

Review 7.  Primary intracranial mucosa-associated lymphoid tissue lymphoma. A report of two cases and literature review.

Authors:  Cristina Sebastián; Ana Carmen Vela; Ramón Figueroa; Miguel Ángel Marín; Jorge Alfaro
Journal:  Neuroradiol J       Date:  2014-08-29

8.  Cerebral localized marginal zone lymphoma presenting as hypothalamic-pituitary region disorder.

Authors:  E Broussalis; J Kraus; A B Kunz; G Luthringshausen; M McCoy; W Muss; G Hutarew; G Ladurner; E Trinka; M Killer-Oberpfalzer
Journal:  Case Rep Neurol       Date:  2011-05-31

9.  Dural MALT lymphoma with disseminated disease.

Authors:  Kelly Matmati; Nabil Matmati; Yusuf A Hannun; Zoran Rumboldt; Sunil Patel; John Lazarchick; Robert Stuart; Pierre Giglio
Journal:  Hematol Rep       Date:  2010-12-03

10.  Primary CNS lymphoma other than DLBCL: a descriptive analysis of clinical features and treatment outcomes.

Authors:  Taekyu Lim; Seok Jin Kim; Kihyun Kim; Jung-Il Lee; Do Hoon Lim; Duk Joo Lee; Kyung Kee Baek; Ha Yeon Lee; Boram Han; Ji Eun Uhm; Young Hyeh Ko; Won Seog Kim
Journal:  Ann Hematol       Date:  2011-04-09       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.